Theseus Pharmaceuticals Inc
(NAS:THRX)
$
4.06
0 (0%)
Market Cap: 181.28 Mil
Enterprise Value: -20.19 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 24/100 Theseus Pharmaceuticals Inc at Wedbush PacGrow Healthcare Conference (Virtual) Transcript
Aug 10, 2022 / 02:20PM GMT
Release Date Price:
$8.38
(-3.46%)
David Matthew Nierengarten
Wedbush Securities Inc., Research Division - MD & Head of Healthcare of Equity Research
Thank you, everyone, for joining us today at the Wedbush PacGrow Healthcare Conference. Today, we're going to be discussing targeted oncology and several different flavors here. With us today, we have representatives from 4 of those companies, and I will turn the mic over to them in one second to give a brief intro or at least say who they are.
(Operator Instructions) And we will just turn it over. Nima, let's start with you, and we'll go kind of round-robin on a quick intro.
Nima Farzan
Kinnate Biopharma Inc. - President, CEO & Director
All right. Thanks, David. Thanks for having me. Nima Farzan, I'm the CEO of Kinnate Biopharma.
David Matthew Nierengarten
Wedbush Securities Inc., Research Division - MD & Head of Healthcare of Equity Research
Tim?
Timothy P. Clackson
Theseus Pharmaceuticals, Inc. - CEO, President & Director
Hi,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot